Genomics

There are many companies that provide direct-to-consumer genomics services and their prices are dropping exponentially. They are rapidly on the way to mass market affordability and patients will routinely be able to run tests and present analysis results to their clinicians.

Source: Swan, M, 2009. Review of Multigenic condition risk assessment in direct-to-consumer genomics offerings.